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proteins. Upon completion of the human genome, eight catalytically active RNases (numbered 1–8)
were identiﬁed. These structurally distinct RNases, characterized by their various catalytic differ-
ences on different RNA substrates, constitute a gene family that appears to be the sole vertebrate-
speciﬁc enzyme family. Apart from digestion of dietary RNA, a wide variety of biological actions,
including neurotoxicity, angiogenesis, immunosuppressivity, and anti-pathogen activity, have been
recently reported for almost all members of the family. Recent evolutionary studies suggest that
RNases started off in vertebrates as host defence or angiogenic proteins.
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Human ribonucleases (RNases) together with the RNases of
other mammals and vertebrates constitute an extensive super-
family of homologous enzyme proteins that has been the subject
of intense biochemical, structural, and evolutionary studies for
over half a century (for general reviews, see [1–3]). The proto-
type of this superfamily, bovine pancreatic ribonuclease A
(Fig. 1, [4], 7RSA-PDB), also known as RNase A, is perhaps the
best-characterized of all known mammalian enzyme proteins
(for review, see [5]). All superfamily members are extracellular
proteins and share speciﬁc elements of sequence signature, a
disulﬁde-bonded tertiary structure, and the ability to degrade
RNA; moreover, several mammalian members have been found
to bind with femtomolar afﬁnity to the ribonuclease inhibitor
protein (RI) (for review, see [6]). This vertebrate (RNase A) super-
family of proteins is distinct from two other well-investigated
superfamilies of T1 and T2 ribonucleases, which are not homolo-
gous with RNase A. While T1 RNases exist only in bacteria and
fungi, T2 ribonucleases are found in protozoans, plants, bacteria,chemical Societies. Published by E
onuclease inhibitor protein;
cationic protein; ang, angio-
ded RNA
Biology, University of Naples
81 679233.viruses and animals, humans included (for a recent review, see
[7]).
In ruminants and other mammals with ruminant-like diges-
tion the major function of pancreatic ribonucleases is to degrade
dietary RNA and to recover RNA-nitrogen from the intestinal ﬂora
[2,8]. However, many members of the vertebrate RNase super-
family evolved to perform important nondigestive functions
including neurotoxicity, angiogenesis, immunosuppressivity, and
antibacterial as well as antiviral actions [9]; indeed, the dynamic
evolutionary history of this superfamily is one of its most intrigu-
ing features [3,10]. The ﬁnding that several superfamily members
were shown to possess antipathogenic activities [11] together
with the recent studies on their molecular evolution have sug-
gested that ancestral RNases started off in vertebrates as host de-
fence or angiogenic effectors [3,9,10,12,13]. The initial sequencing
and analysis of the human genome revealed several gene families
that are unique to vertebrate species; the human RNase gene
family is one of these vertebrate-speciﬁc families and is the only
one that encodes proteins with enzymatic activity [14]. In the
whole human genome eight catalytically active ribonucleases
[15] have been identiﬁed together with only other ﬁve open read-
ing frames (ORFs) which encode proteins virtually unable to de-
grade RNA [10]. In this article the information available on the
eight active RNase proteins will be summarized; in particular,
their structural and catalytic properties as well as their intriguing
special biological actions will be comparatively analyzed and
discussed.lsevier B.V. All rights reserved.
Fig. 1. Ribbon diagram of the three-dimensional structure of ribonuclease A, the
prototype of the vertebrate RNase superfamily ([4], 7RSA-PDB). The predominant
elements of secondary structure are a long four-stranded antiparallel b-sheet and
three short a-helixes. The enzyme is cross-linked by four disulﬁde bonds.
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In the human genome eight RNase genes were ﬁrst identiﬁed,
forming a cluster of about 368 kb [15]. This was conﬁrmed later
by a more extensive analysis and the eight structurally distinct
proteins encoded by the previously reported genes were referred
as ‘‘canonical” RNases [10]. This enzyme family (Fig. 2) includes:
RNase 1, or pancreatic RNase [16], expressed in pancreas as well
as in other organs and tissues; RNase 2, the so-called nonsecre-
tory RNase [17], also named eosinophil-derived neurotoxin
(EDN) [18]; RNase 3, also named eosinophil cationic protein
(ECP) [19]; RNase 4 [20], detected in several somatic tissuesFig. 2. Amino acid sequence alignment of the eight human canonical ribonucleases. The c
rhombus. A positional change of a cysteine in RNase 8 is indicated by black triangles.
indicated. The alignment was generated by CLUSTAL W. The references for the sequenc[21]; RNase 5, or angiogenin (ang) [22]; RNase 6 or RNase K6
[23]; RNase 7, an epithelial-derived antimicrobial protein [24];
and RNase 8, the last discovered active human RNase expressed
uniquely in placenta [15]. Among common characteristics of this
gene family, the coding sequences of all eight RNases encode a
signal sequence typical of secreted proteins [10,15]. The mature
enzymes are small proteins and the previously reported three-
dimensional (3D) structures of RNases 1–5 and 7 [25–30] are sim-
ilar to the kidney-shaped tertiary fold of bovine RNase A (Fig. 1).
To date no 3D structures for RNases 6 and 8 have been deter-
mined. With the exception of RNase 5 (Fig. 2), which has six cys-
teines that form three disulﬁde bonds, all other proteins possess
eight cysteines that form four disulﬁde bonds in the folded forms
of the proteins. Moreover all eight sequences have an invariant
catalytic triad, which includes His-12, His-119 (within the con-
served sequences FXXQH and PVHXD, respectively) and Lys-41
(within the typical consensus pattern CKXXNTF). Recently, other
ﬁve divergent sequences with signiﬁcant similarity to the se-
quence of the enzymes described above were identiﬁed in the
whole human genome [10]. These additional genes, corresponding
to the so-called RNases 9–13, are also located in the same chro-
mosome cluster in the conﬁguration shown in Fig. 3 and seem
to be related to male-reproductive functions [10]. RNases 9–13
keep the disulﬁde bridge pattern but do not have all the speciﬁc
elements necessary to support ribonuclease activity [10]. The last
identiﬁed gene (RNase 13) is about 9 kb away from RNase 7 to-
ward the centromere and has a transcriptional direction opposite
to those of RNase 7 and RNase 8. The other four noncanonical
RNase sequences (RNases 9–12) are instead toward the telomere.
3. Classiﬁcation, molecular diversity and properties of the eight
human canonical RNases
In humans the RNase proteins described in Fig. 2 are widely dis-
tributed in various organs, tissues and body ﬂuids and, for some ofonserved amino acids are boxed with the three catalytic residues indicated by black
Pyroglutamic acid (<Q) at position 1 in RNase 4 and at position 1 in RNase 5 is
es are given in the text.
Fig. 3. Chromosomal locations of all human RNase genes. The transcription of the genes coding for both canonical (RNases 1–8) and noncanonical (RNases 9–13)
ribonucleases is in both directions as indicated by ﬁlled arrows. RNases 9–13 are potentially functional genes, but do not possess all elements to support ribonucleolytic
activity. RNase 2-ps, indicated by an open arrow, is a pseudogene. Figure modiﬁed, from [10].
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cosylation patterns, have been shown to exist. These enzymes, to-
gether with other members of the vertebrate RNase superfamily,
on the basis of their structural, catalytic and/or biological charac-
teristics, can be essentially grouped, as already proposed [31–33],
into four different RNase types. The evolutionary relationships
among these RNases shown in Fig. 4 strongly support the classiﬁ-
cation into four distinct protein types. The tree suggests a close
relationship (bootstrap = 100%) between RNase 2 and RNase 3 as
well as between RNases 7 and 8; it also indicates that RNases 2,
3, 6, 7, and 8 are closely related to one another, forming a separate
group from RNase 1, RNase 4, and RNase 5 [15]. In this regard, it is
worth mentioning again that human RNases are secretory proteins
characterized by a typical signal peptide; therefore, the two main
RNase types (RNase 1 and RNase 2, often named in the past ‘‘secre-
tory” and ‘‘nonsecretory” RNases, respectively) were more properly
designated [31] pancreatic-type (pt) and nonpancreatic-type (npt)
RNases, respectively.Fig. 4. Unrooted phylogenetic tree of the eight human canonical ribonucleases. As
shown, RNases 2, 3, 6, 7, and 8 are closely related to one another, forming a separate
group from RNase 1, RNase 4 and RNase 5. The neighbour-joining method was used
with Poisson-corrected distances and 2000 bootstrap replications. Bootstrap
percentages are shown on interior branches.3.1. RNase 1
The pancreatic ribonuclease of mammals, despite its name, is
expressed in a wide variety of tissues and is one of the most rapidly
evolving proteins. High levels of pancreatic RNases are only found
in several herbivores, generally combined with ancestral gene
duplications with specialization of a digestive pancreatic enzyme,
like in ruminants and colobines (langur monkeys, a leaf-eating pri-
mate species with ruminant-like digestion) [2,8]. In ruminants, for
example, three distinct genes encode the ptRNases predominantly
found in pancreas, seminal vesicles and brain [34]. Humans instead
have only one such gene and the major function of the pancreatic
enzyme is not a digestive one [2,35]. All human ptRNases found in
various organs, at similar or higher levels than in pancreas [36] are
in fact products of the same RNase 1 gene [34]. However, differen-
tial post-translational processing occurs; in particular, the glyco-
sylation patterns of the RNase 1 enzymes puriﬁed from urine
[37], seminal plasma [38], brain [39], and kidney [40] were found
to be quite different. Concerning the controversial origin of this
RNase protein in blood serum and other ﬂuids, a possible answer
could be found in the ﬁnding that human endothelial cells selec-
tively express large amounts of RNase 1 [41]. It was suggested that
the enzyme might also be involved in the regulation of vascular
homeostasis and that a signiﬁcant part of the protein present in
various organs could originate from the endothelium of arteries,
veins, and capillaries. Thus RNase 1 not only is a digestive enzyme
but, thanks to its wide extracellular distribution ascribable to its
high release by blood vessel endothelial cells [41], it might have
important physiological implications.
Like other mammalian ptRNases, the human RNase 1 enzyme
has a pH optimum value towards RNA of 8.0, efﬁciently hydrolyzes
20,30-cyclic nucleotides and, as a substrate preference, is more
effective towards poly(C) than poly(U) [31]. Under physiological
salt conditions, RNase 1 is the most powerful enzyme to degrade
double-stranded RNA (dsRNA) within the vertebrate RNase super-
family [42]. According to a mechanism previously proposed [31],
the remarkable activity of the enzyme against dsRNA (two orders
of magnitude more active than bovine RNase A) is due to the pres-
ence of additional noncatalytic basic residues (R4, K6, R32, R39,
and K102) which cooperatively contribute to the binding and
destabilization of the double-helical RNA molecule [33]. The hu-
man enzyme, with activity values two orders of magnitude higher
than those of RNase A, can also cleave poly(A) and the RNA compo-
nent of DNA:RNA hybrid molecules [43,44]. Recently, it has been
reported that it has a higher endonucleolytic activity than bovine
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might act as an extracellular RNA scavenger contributing to the
normalization of serum viscosity and also it may be involved in
nonspeciﬁc response to pathogenic RNA molecules [33]. The possi-
ble participation of RNase 1 to inﬂammatory and immune re-
sponses [46] has been correlated to its ability to induce
phenotypic and functional maturation of dendritic cells as well
as production of a variety of soluble mediators including cytokines,
chemokines and growth factors. It was also reported to inactivate
HIV and might protect the foetus during pregnancy [47]. Recently,
to better understand the basis of these special activities, the solu-
tion structure and dynamics of recombinant wild-type (wt) RNase
1 have been determined by NMR spectroscopy methods [25]. To
date no 3D structure of wtRNase 1 has been determined except
for that one reported in complex with the RI [48]. In the NMR study
[25], the side-chains of several surface basic residues have been
found to adopt in solution multiple conformations, thus proposed
to be crucial for the biological activities of the human enzyme. It
is worth pointing out that these residues are the same basic resi-
dues mentioned above which were believed to be responsible of
the remarkable activity of RNase 1 on dsRNA [42] and to contribute
to its catalytic versatility [33].
3.2. RNase 2 and RNase 3
These ribonucleases are two of the major secretory proteins of
human eosinophil granules which have been isolated and named
EDN and ECP prior to their identiﬁcation as members of the verte-
brate RNase superfamily [49]. RNase 2/EDN and RNase 3/ECP are
very basic proteins and share a 67% primary structure identity
(Fig. 2); their remarkable structural similarities also appear in the
previously reported crystal structures [26,27]. Both proteins are
products of a recent gene duplication in an ancestral primate and
their rapid divergence (Fig. 4), indicative of responsiveness to unu-
sual evolutionary pressure, has been reviewed previously [50].
Unlike RNase 3, which is an eosinophil-speciﬁc protein, RNase 2
occurs also in spleen [51], liver [52,53], kidney [40], placenta [54],
and urine [17]. The primary structures of RNases 2 and 3 (Fig. 2)
are only 32% and 26% identical, respectively, to that of RNase 1.
In particular, several amino acid residues that are considered cata-
lytically important in all mammalian ptRNases (K7, R10, K66, and
F120) are replaced in both enzymes in a nonconservative way
(Fig. 2). In addition, the amino acid sequences of RNase 2 and
RNase 3 (Fig. 2) include ﬁve and three potential sites for aspara-
gine-linked glycosylation, respectively, and their natural N-glycan
structures, containing complex oligosaccharides, are very different
from that of RNase 1 [43].
Concerning their catalytic features, both RNases 2 and 3 (in con-
trast to RNase 1) prefer poly(U) over poly(C), are totally inactive on
poly(A) and dsRNA, do not hydrolyze 20:30-cyclic nucleotides, and
show a pH optimum value for the degradation of yeast RNA be-
tween 6.5 and 7.0 [55,56]. Despite their remarkable sequence iden-
tity, these enzymes display some different catalytic and biological
properties. While the ribonucleolytic activity of RNase 2 toward
yeast RNA as substrate is high and comparable to that of RNase 1
[53,55], RNase 3 is about two orders of magnitude less active on
this substrate [56,57]. These two RNase proteins show similar neu-
rotoxic potency [49] linked to their ribonucleolytic activity [53].
RNase 3/ECP is less neurotoxic but is a more potent helmintotoxin
[19]. RNase 2/EDN does not display any bactericidal activity, but
has a speciﬁc antiviral action (dependent on RNase activity)
against respiratory syncytial virus (RSV) and HIV [58–61]. More-
over RNase 2/EDN has been included in the novel class of proteins
called alarmins for its ability to promote maturation and chemo-
taxis of dendritic cells, contributing to the modulation of both in-
nate and adaptive immunity [46,62]. RNase 3/ECP hasbactericidal, antiviral and antiparasitic activities, and also inhibits
mammalian cell growth [63], but its ribonucleolytic activity does
not appear to be necessary for cytotoxicity [64]. The molecular
mechanism of ECP cytotoxicity has been reviewed extensively
[11]; both cell toxicity and bactericidal action of RNase 3/ECP cor-
relate with its membrane disruption capability and have been
linked to aromatic and cationic residues located on the surface of
the protein [63,65].
3.3. RNase 4
There are peculiar features that characterize RNase 4 and distin-
guish it from the other human canonical ribonucleases: Its amino
acid sequence (119 residues) is the shortest (Fig. 2) and the most
evolutionarily conserved among different mammalian species
(about 90% identity with bovine, porcine, and rat RNases); it con-
tains a unique deletion of two residues (positions 77 and 78, RNase
1 numbering), and no motifs for N-linked carbohydrates; in addi-
tion, like RNase 5, the ﬁrst amino acid residue is a pyroglutamic
acid [20,66,67]. Human RNase 4 was ﬁrst isolated from the condi-
tioned medium of a colon carcinoma tumor cell line [68] and later
from normal plasma [20]. A large mRNA coding for this RNase was
detected in several somatic tissues including liver (with the high-
est level), pancreas, lung, heart, kidney, and placenta, but not brain
[21]. At present it is not known which cells selectively express
RNase 4, nor whether the levels of its mRNA correlate with that
of the protein.
The enzyme is structurally more similar to RNase 1 (43% iden-
tity) than to RNase 2 (31% identity) but shares some catalytic prop-
erties with both RNase types. Like RNases 2 and 3, RNase 4 strongly
prefers poly(U) as a substrate over poly(C) but, on the contrary, it
shows hydrolytic activity towards 20:30-cyclic nucleotides [68]
which, indeed, is a catalytic feature of RNase 1 and other mamma-
lian ptRNases. An explanation for its strong preference for uridine
to cytidine was provided by the determination of the crystal struc-
ture of the recombinant protein in complex with d(Up) [28]. Fur-
thermore, the unique active-site pocket of RNase 4, adapted to
recognize uridine, together with the remarkable interspecies simi-
larity of this protein, has suggested [20] the existence of a strong
evolutionary pressure to maintain a structure that implies a spe-
cialized biological function. This has yet to be found, although no
investigations in this direction have been tried.
3.4. RNase 5
This protein is an unusual member of the vertebrate RNase
superfamily in that it is a potent inducer of new blood vessel for-
mation in vivo [69] and exhibits an atypical ribonucleolytic activity
which, although weak, is essential for angiogenesis [68]. Angioge-
nin/RNase 5 was originally isolated from tumor cell conditioned
medium [69] and later from normal serum [70]; it was subse-
quently found to have a wide tissue and organ distribution and this
has led to the suggestion that it may have other biological func-
tions [71]. Once its amino acid sequence was determined [22] it
was identiﬁed as a ribonuclease. Despite its structural similarity
(Fig. 2) to RNase 4, RNase 1, and RNase 2 (39%, 35%, and 27% iden-
tity, respectively), RNase 5 shows an extremely weak RNA cleaving
activity. Although its crystal structure [29,72] is similar to that of
RNase A (Fig. 1) and to that of RNase 1 [25] there is a notable dif-
ference in the catalytic active-site. The pyrimidine binding site of
RNase 5 is ‘‘obstructed” by the side-chain of Gln-117 (correspond-
ing to residue 122, RNase 1 numbering, Fig. 2); this blockage is also
associated with a remarkable different orientation of the C-termi-
nal segment of the protein compared to that of RNase A [29,72,73].
The reﬁned high-resolution crystal structure of RNase 5 also re-
vealed details of the cell-binding region and nuclear localisation
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biological functions [72]. To stimulate blood vessel growth, RNase
5 must be transported to the nucleus; thus, the receptor binding,
nuclear translocation, and ribonucleolytic activity are all essential
for its actions. Mechanistic studies have demonstrated that RNase
5/ang undergoes nuclear translocation in endothelial cells where it
binds to the promoter of ribosomal DNA and stimulates rRNA tran-
scription, hence playing an essential role in cell proliferation [74].
During the last two decades an enormous volume of work has
been dedicated to the study of the actions of this protein. Several
reviews have considered ang in particular [75,76]. Two recent pa-
pers [77,78] describe the current understanding of the mechanism
of ang action based on transcriptional activation of rRNA, in a num-
ber of physiological and pathological processes. In these reviews,
the involvement of ang in motor neuron physiology and in amyo-
tropic lateral sclerosis have been also considered. Moreover, a gen-
eral function as host defence protein has been proposed for ang
based on its microbicidal activity [79]; this ﬁnding and the related-
ness of RNase 5/ang to ﬁsh RNases [12,13] support the hypothesis
[10] that ang may represent the ancestor of the vertebrate RNase
superfamily. Like other mammalian RNases, this protein is strongly
inhibited by the RI which has been recently reported to regulate
neovascularization and other biological actions of ang in vivo [80].
Although RNase 5 was reported to be able to catalyze the deg-
radation of rRNA and tRNA [68,81], the physiological substrate is
still unknown. However, very recent reports [82,83] have high-
lighted another intriguing function of this protein. Under stress
(oxidative, heat shock, or ultraviolet irradiation), ang cleaves tRNA
to produce and accumulate tRNA-derived small RNAs (tiRNAs);
this activity produces arrest of protein synthesis in order to con-
serve energy for repair of stress-induced damage. The inhibition
of stress-induced tiRNA production and translational arrest, caused
by the RNase inhibitor RI, is one of the reported evidences that sup-
port the involvement of RNase 5/ang in cell defence against stress
[82,83].
3.5. RNase 6
This protein was the sixth member of human RNase family to be
characterized and it was found as the result of a search for a human
ortholog for bovine kidney ribonuclease (RNase K2). For its evolu-
tionary relationships with RNase K2 (72% sequence identity) it was
named RNase K6 [23]. RNase 6, as a protein, was not puriﬁed form
any human tissue or ﬂuid, but it was identiﬁed as a genomic seg-
ment and localized on chromosome 14. A single mRNA transcript
was detected in many tissues including lung (with the highest le-
vel), heart, brain, placenta, liver, skeletal muscle, kidney, and pan-
creas [23]. The deduced amino acid sequence of RNase 6 (Fig. 2) is
more similar to that of RNase 2 (47%) than to that of RNase 1 (38%).
The ribonucleolytic activity of the recombinant protein tested
against yeast RNA was found to be about 40-fold lower than that
of RNase 2. Unfortunately, no information concerning substrate
preference, pH optimum and other catalytic properties for this en-
zyme is presently available. The detection of mRNA transcripts
encoding RNase 6 in both neutrophils and monocytes has sug-
gested a role for this protein in host defence but, to date, it is an
enzyme protein in search of a physiologic function.
3.6. RNase 7 and RNase 8
The amino acid sequences of these two human proteins (Fig. 2)
are remarkably similar (78% identity); this has suggested [15] that
they have originated from a relatively recent gene duplication
(Fig. 4). However, although RNase 7 and RNase 8 show a very high
similarity in their structure, their physiological functions seem to
be quite different. While RNase 7 is expressed in various epithelialtissues and organs [24,84], RNase 8 has been shown to be ex-
pressed uniquely in the placenta [15].
RNase 7 was ﬁrst puriﬁed from skin-derived stratum corneum
as a result of an effort to characterize active antimicrobial agents
in healthy human skin [24]. The protein is mainly secreted by
keratinocytes, and its expression can be induced in primary cul-
tures by interleukin, interferon and bacteria challenge [24]. The
corresponding gene was also identiﬁed in the human genome se-
quence [84] and mRNA expression was detected in skin as well
as in respiratory tract, genitourinary tract, liver, kidney, skeletal
muscle, and heart [24,84]. RNase 7 displays a strong bactericidal
activity in the low micromolar concentration range against a num-
ber of both Gram-positive and Gram-negative bacteria, even at
4 C; its bactericidal activity has recently been linked to the capac-
ity of the protein to permeate the bacteria membrane [30]. The
determination of the 3D NMR solution structure of recombinant
RNase 7 together with assays performed with several RNase 7 vari-
ants have demonstrated that the ribonucleolytic activity is not
essential for the antibacterial action. In addition, a cluster of four
speciﬁc lysines (K1, K3, K111, and K112) crucial for the antimicro-
bial mechanism of action of the protein was identiﬁed [30]. Puri-
ﬁed natural protein exhibited a catalytic activity value which
was about 50-fold higher than that of RNase 3/ECP [24]. Recombi-
nant RNase 7 was also reported to show on yeast RNA a ribonucle-
olytic activity about 8-fold lower than that of RNase 1, but twice
that of RNase 8 [84]. Unfortunately, no other catalytic properties
for these two RNases are available.
RNase 8 has most of all the structural characteristics of mamma-
lian ribonucleases (Fig. 2). An unusual feature is that the cysteine
residue at position 84 (RNase 1 numbering), conserved among all
other RNases, has changed to glycine, while a new cysteine residue
has appeared at position 69 (RNase 1 numbering). This unusual cys-
teine was suggested to form a possible interchain disulﬁde bond by
pairing with the otherwise uncoupled cysteine 26 (RNase 1 num-
bering) [15]. Recombinant RNase 8 was reported to be inactive as
an antibacterial protein [15], but more recently it has been demon-
strated its potent antimicrobial activity at micro- or nanomolar
concentrations against various clinically relevant microorganisms.
The killing activity of RNase 8 was found to be speciﬁc for microor-
ganisms (various Gram-positive and Gram-negative strains as well
as Candida albicans) and did not affect human cells; thus it may play
a role in protecting the placenta from infection [85].Acknowledgement
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